RR 416 - 2014 NATS Parkinson
dc.contributor.author | Núcleo de Avaliação de Tecnologias em Saúde (NATS) | |
dc.date.accessioned | 2015-04-28T19:27:34Z | |
dc.date.available | 2015-04-28T19:27:34Z | |
dc.date.issued | 2014-07-25 | |
dc.description.abstract | Assertr, Cefelic®, Dieloft®, Sered®, Serenata®, Tolrest® Seronip®, Serolift®, Sertralin®, Zoltralina®, Zysertin® | pt_BR |
dc.identifier.uri | https://bd.tjmg.jus.br/jspui/handle/tjmg/6147 | |
dc.subject | doença neurológica | pt_BR |
dc.subject | Levodopa | pt_BR |
dc.subject | Carbidopa | pt_BR |
dc.subject | Pantoprazol | pt_BR |
dc.subject | Sertralina | pt_BR |
dc.title | RR 416 - 2014 NATS Parkinson | pt_BR |